United States (US)-based pharmaceutical major and vaccine maker Moderna has said that the studies of its two-dose mRNA COVID-19 vaccine in teenagers has shown an efficacy rate of 96 per cent, Hindustan Times.
The study was conducted among adolescent participants from the age group of 12-17 years. The company claims that the vaccine has shown no serious safety problems and that it will ll build up its production capacity to boost the supplies of its vaccine.
The company has also recently released the results of preliminary human trials showing that two types of booster shots of its vaccine helped bolster immune responses against variants that surfaced in South Africa and Brazil.
The company had recently announced investments in its US plants and overseas contractors to raise the production to as much as three billion doses next year.
Moderna Inc's vaccine is already being widely used in the US for inoculation of American adults against COVID-19.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.